
---
title: '民生证券：首款国产新冠小分子药附条件获批 看好产业链业绩兑现'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=698'
author: 证券时报网
comments: false
date: Tue, 26 Jul 2022 14:16:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=698'
---

<div>   
<p>证券时报网讯，民生证券指出，国内首个新冠小分子药物阿兹夫定获批具有里程碑意义，综合考虑国内疫情以及海外新冠药物的市场销售情况，我们认为阿兹夫定产业链将有较大受益，建议关注和真实生物签订协议供应国内生产销售的<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000756" code="000756">新华制药</a>、签订委托生产协议的<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603229" code="603229">奥翔药业</a>和<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600062" code="600062">华润双鹤</a>以及签订独家商业化战略协议的<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600196" code="600196">复星医药</a>，维持“推荐”评级。</p>

                  
</div>
            